ziopharm oncology, inc., is a biopharmaceutical company focused on the discovery and development of new cancer therapies. we are applying the latest technologies in cancer research to develop safer, more precise therapeutics to improve care and quality of life for patients.
Company profile
Ticker
TCRT
Exchange
Website
CEO
Laurence James Neil Cooper
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EASYWEB INC, ZIOPHARM ONCOLOGY INC
SEC CIK
Corporate docs
Subsidiaries
ZIOPHARM Oncology, Ltd ...
IRS number
841475642
TCRT stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Departure of Directors or Certain Officers
22 Feb 24
8-K
Other Events
20 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
1 Feb 24
8-K
Other Events
29 Jan 24
8-K
Departure of Directors or Certain Officers
22 Jan 24
Transcripts
TCRT
Earnings call transcript
2023 Q1
10 May 23
TCRT
Earnings call transcript
2022 Q4
7 Mar 23
TCRT
Earnings call transcript
2022 Q3
14 Nov 22
TCRT
Earnings call transcript
2022 Q2
15 Aug 22
TCRT
Earnings call transcript
2022 Q1
16 May 22
TCRT
Earnings call transcript
2021 Q4
30 Mar 22
TCRT
Earnings call transcript
2021 Q3
9 Nov 21
TCRT
Earnings call transcript
2021 Q3
8 Nov 21
TCRT
Earnings call transcript
2021 Q2
10 Aug 21
TCRT
Earnings call transcript
2021 Q2
9 Aug 21
Latest ownership filings
SC 13G/A
DISCOVERY CAPITAL MANAGEMENT, LLC / CT
14 Feb 24
SC 13G/A
MSD Partners, L.P.
13 Feb 24
4
Dale Curtis Jr. Hogue
23 Jan 24
4
Dale Curtis Jr. Hogue
3 Jan 24
3
Dale Curtis Jr. Hogue
3 Jan 24
4
Kevin S. Sr. Boyle
5 Sep 23
144
Notice of proposed sale of securities
1 Sep 23
4
Robert W Postma
8 Jun 23
4
Robert Hofmeister
8 Jun 23
4
Mary Thistle
8 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.94 mm | 11.94 mm | 11.94 mm | 11.94 mm | 11.94 mm | 11.94 mm |
Cash burn (monthly) | 2.12 mm | 3.32 mm | 2.89 mm | 2.90 mm | 2.12 mm | 2.49 mm |
Cash used (since last report) | 15.29 mm | 23.88 mm | 20.79 mm | 20.90 mm | 15.30 mm | 17.93 mm |
Cash remaining | -3.35 mm | -11.94 mm | -8.85 mm | -8.96 mm | -3.35 mm | -5.99 mm |
Runway (months of cash) | -1.6 | -3.6 | -3.1 | -3.1 | -1.6 | -2.4 |
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 14 |
Opened positions | 1 |
Closed positions | 82 |
Increased positions | 1 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 64.94 mm |
Total shares | 16.45 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
White Rock Capital Management | 9.63 mm | $23.30 mm |
Hardie Robert D. | 6.24 mm | $0.00 |
Allred Capital Management | 253.00 k | $17.89 mm |
Sugarloaf Wealth Management | 65.50 k | $4.63 mm |
Cerity Partners | 54.60 k | $3.86 mm |
Redwood Wealth Management | 50.10 k | $3.54 mm |
Welch | 43.00 k | $3.04 mm |
AdvisorNet Financial | 42.33 k | $2.99 mm |
Mutual Advisors | 27.10 k | $1.92 mm |
Raymond James & Associates | 16.76 k | $1.19 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Jan 24 | Dale Curtis Jr. Hogue | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.12 | 600,000 | 72.00 k | 600,000 |
29 Dec 23 | Dale Curtis Jr. Hogue | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.071 | 41,667 | 2.96 k | 41,667 |
29 Dec 23 | Dale Curtis Jr. Hogue | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.071 | 150,000 | 10.65 k | 150,000 |
1 Sep 23 | Kevin S. Sr. Boyle | Common Stock | Sell | Dispose S | No | Yes | 0.1403 | 68,014 | 9.54 k | 798,236 |